AIkido Pharma logo
AIkido Pharma AIKI

Quarterly report 2025-Q3
added 11-10-2025

report update icon

AIkido Pharma Financial Statements 2011-2026 | AIKI

Annual Financial Statements AIkido Pharma

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

19.6 M 16.6 M 16.9 M 33.8 M 55.4 M 2.96 M 5.66 M 7.03 M 4.01 M 3.47 M 1.33 B 555 K 580 K 5.49 B

Shares

6.18 M 5.23 M 5.33 M 4.85 M 33 M 2.51 M 1.9 M 1.3 M 903 K 398 K 19.7 M 1.32 K 1.32 K 2.63 M

Historical Prices

3.17 3.17 3.17 6.97 20.2 20.1 52.6 89 72.8 111 1.14 K 5.77 K 14.3 K 20.3 K

Net Income

-14.7 M -22.9 M -22.1 M -7.17 M -12.3 M -4.18 M 1.73 M -3.31 M -6.48 M -51.5 M -30.5 M -18 M - -3.46 M

Revenue

18.1 M 2.04 M - - - 9 K 28 K 1.24 M 877 K 33 K 10 K 27 K - 821 K

Cost of Revenue

- - - - - 9 K 28 K - - - - 3 K - -

Gross Profit

- - - - - - - - - - 10 K 24 K - 821 K

Operating Income

-11.5 M -21.8 M -14.3 M -9.44 M -6.55 M -5.68 M -6.87 M -3.82 M -8.55 M -52 M -30.6 M -15.3 M -3.47 M -4.19 M

Interest Expense

- - - - -5.79 M 1.5 M - - - - - - 4 K -

EBITDA

-11.4 M -21.7 M -14.3 M -9.44 M -736 K -2.7 M -5.43 M -2.45 M -6.41 M -45.7 M -20.8 M -15.1 M - -4.28 M

Operating Expenses

29.7 M 23.8 M 14.3 M 9.44 M 6.55 M 5.69 M 6.9 M 5.06 M 9.43 M 52 M 30.6 M 15.4 M 3 M 5.17 M

General and Administrative Expenses

29.7 M 23.8 M 11.7 M 7.73 M 4.06 M - 3.06 M 3.68 M 4.58 M 5.13 M 20.8 M 15.1 M - -

All numbers in USD currency

Quarterly Income Statement AIkido Pharma

2025-Q3 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

15.4 M 6.98 M 6.33 M 6.06 M 6 M 5.93 M 5.35 M 4.83 M 5.31 M 5.02 M 5.34 M 5.25 M 89.3 M 5.28 M 5.27 M 5.27 M 60.3 M 34.9 M 35 M 33 M 9.2 M 4.83 M 2.44 M 2.12 M 2.01 M 2.01 M 8.54 M 2.01 M 1.55 M 6.23 M 6 M 4.96 M 4.94 M 4.94 M 4.16 M 3.06 M 2.71 M 2.54 M 1.74 M 1.51 M 1.51 M 1.51 M 28.1 M 16.9 M 4.79 M 3.77 M 1.34 M 706 K 691 K 814 K 208 K 208 K 186 K 155 K 128 K 2.56 M 2.45 M

Net Income

125 M - -4.21 M -6.12 M -5.44 M - -3.54 M -8.66 M -3.76 M - -6.24 M -5.08 M -3.54 M - -47 K -1.35 M -3.96 M - -2.02 M -2.31 M -8.33 M - -3.36 M -644 K -1.15 M - -1.89 M -398 K -1.49 M - 459 K -1.86 M -919 K - -446 K -2.08 M -49 K - -2.73 M -40.3 M -4.09 M - -5.14 M -11.6 M -7.96 M - -9.28 M -807 K -3.7 M - -708 K -405 K -834 K - -913 K -1.01 M -235 K

Revenue

50.8 M - 4.04 M 6.17 M 1.37 M - 963 K 71 K - - - - - - - - - - - - - - - - - - - - - - 314 K 311 K 327 K - 314 K 177 K 72 K - - - 2 K - 2 K 3 K 4 K - 2 K 213 6 K - 16.7 K - 210 K - 198 K 186 K 306 K

Cost of Revenue

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 836 K 361 K - - 336 K -54 K - - - - - - - - - - - - - - - - -

Gross Profit

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 213 5.76 K - - - - - - - -

Operating Income

-1.6 M - -3.2 M -2.74 M -2.8 M - -3.1 M -9.01 M -3.83 M - -5.1 M -2.3 M -3.8 M - -1.78 M -2.76 M -2.32 M - -966 K -1.79 M -2.4 M - -902 K -888 K -713 K - -1.95 M -1.26 M -1.58 M - -959 K -777 K -969 K - -1.49 M -1.62 M -1.56 M - -1.96 M -40.3 M -4.12 M - -5.16 M -11.6 M -8.01 M - -9.32 M -947 K -911 K - -634 K -669 K -1.06 M - -789 K -1.02 M -1.11 M

Interest Expense

- - - - - - - - - - -1.14 M -2.78 M 268 K - 1.73 M 1.41 M -1.64 M - -1.05 M -519 K -5.93 M - - - - - - - - - - - - - 16 K 55 K - - 7 K -5 K - - 17 K 11 K 6 K - - 1 K - - - - - - - - -

EBITDA

- - - - -2.78 M - - - -3.83 M - -5.1 M -2.3 M -3.8 M - -1.78 M -2.76 M -2.32 M - -966 K -1.79 M -2.4 M - -902 K -888 K -713 K - -1.93 M -1.24 M -1.58 M - -958 K -434 K -968 K - -1.48 M -1.62 M -2.09 M - -1.96 M -40.3 M -4.12 M - -2.69 M -9.14 M -8.01 M - -9.31 M -942 K -895 K - -583 K -635 K -1.05 M - -736 K -987 K -1.09 M

Operating Expenses

52.4 M - 7.24 M 8.91 M 4.17 M - 4.07 M 9.08 M 3.83 M - 5.1 M 2.3 M 3.8 M - 1.78 M 2.76 M 2.32 M - 966 K 1.79 M 2.4 M - 902 K 888 K 713 K - 1.95 M 1.26 M 1.58 M - 1.27 M 1.09 M 1.3 M - 1.8 M 1.8 M 1.63 M - 1.96 M 40.3 M 4.12 M - 5.16 M 11.6 M 8.01 M - 9.32 M 947 K 917 K - 650 K 669 K 1.06 M - 789 K 1.21 M 1.42 M

General and Administrative Expenses

52.4 M - 7.24 M 8.91 M 4.17 M - 4.07 M 9.08 M 3.83 M - 4.52 M 2.26 M 1.79 M - 1.68 M 2.34 M 1.21 M - 734 K 1.02 M 1.3 M - 892 K 888 K 713 K - 554 K 116 K 142 K - 137 K 174 K 62 K - 65 K 60 K 63 K - 92 K 122 K 226 K - 92 K 51 K 836 K - 2.79 M 661 K 446 K - 543 K 531 K 692 K - 417 K 686 K 932 K

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements AIkido Pharma AIKI
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting AIkido Pharma plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Apellis Pharmaceuticals Apellis Pharmaceuticals
APLS
$ 20.29 -1.98 % $ 2.56 B usaUSA
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.8 -5.29 % $ 4.36 M chinaChina
Axsome Therapeutics Axsome Therapeutics
AXSM
$ 166.62 0.14 % $ 8.29 B usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
AbCellera Biologics AbCellera Biologics
ABCL
$ 3.76 -1.7 % $ 1.12 B canadaCanada
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Burford Capital Limited Burford Capital Limited
BUR
$ 8.45 -3.26 % $ 1.38 B britainBritain
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Capricor Therapeutics Capricor Therapeutics
CAPR
$ 25.77 -4.06 % $ 690 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Codexis Codexis
CDXS
$ 0.97 -5.15 % $ 71.2 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Agenus Agenus
AGEN
$ 3.15 -5.69 % $ 1.13 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Agios Pharmaceuticals Agios Pharmaceuticals
AGIO
$ 28.45 -2.57 % $ 1.65 B usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Завод ДИОД Завод ДИОД
DIOD
- - - russiaRussia
Фармсинтез Фармсинтез
LIFE
- - - russiaRussia
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Cellectis S.A. Cellectis S.A.
CLLS
$ 3.65 -3.95 % $ 116 M franceFrance
Alector Alector
ALEC
$ 2.1 -5.2 % $ 216 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
Altimmune Altimmune
ALT
$ 4.16 -0.12 % $ 295 M usaUSA
Teligent, Inc. Teligent, Inc.
TLGT
- -13.85 % $ 16.1 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Viela Bio, Inc. Viela Bio, Inc.
VIE
- - $ 2.91 B usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
$ 23.99 0.46 % $ 2.93 B usaUSA
Amarin Corporation plc Amarin Corporation plc
AMRN
$ 13.89 -0.32 % $ 5.76 B irlandaIrlanda
AbbVie AbbVie
ABBV
$ 231.88 -1.0 % $ 410 B usaUSA
Blueprint Medicines Corporation Blueprint Medicines Corporation
BPMC
- - $ 8.14 B usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
AIM ImmunoTech AIM ImmunoTech
AIM
$ 0.71 -8.96 % $ 34.1 M usaUSA